As big pharma backs away, Alnylam sees deja vu
April 16, 2014 at 15:23 PM EDT
This week the headline appeared to have some tough news for RNA companies, but Alnylam remains undeterred about the potential of its treatments.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|